^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ONCT-534

    i
    Other names: ONCT-534, GTx-534, SARD compounds, UT-34
    Company:
    Oncternal Therap
    Drug class:
    Androgen receptor inhibitor, Androgen receptor degrader
    Related drugs:
    2ms
    ONCT-534-101: A Clinical Study of ONCT-534 in Subjects with Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P1/2, N=21, Terminated, Oncternal Therapeutics, Inc | N=59 --> 21 | Trial completion date: Jan 2028 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jan 2028 --> Sep 2024; Interim Phase 1 results of ONCT-534 did not show clinically meaningful improvements of disease, including prostate-specific antigen (PSA) levels, in the 20 patients treated in eight dosing cohorts with various doses and schedules of administration.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    ONCT-534
    11ms
    A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. (ASCO-GU 2024)
    Background: Current therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC) include treatment with next-generation androgen receptor signaling inhibitors (ARSIs), such as enzalutamide, darolutamide, and apalutamide, which all target the ligand-binding domain (LBD) of the AR, and abiraterone, an androgen biosynthesis inhibitor. The study was opened for enrollment September 2023. Clinical trial information: NCT05917470.
    Clinical • P1/2 data • Metastases
    |
    AR mutation
    |
    Xtandi (enzalutamide capsule) • abiraterone acetate • Nubeqa (darolutamide) • Erleada (apalutamide) • ONCT-534
    over1year
    A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P1/2, N=59, Not yet recruiting, Oncternal Therapeutics, Inc
    New P1/2 trial • Metastases
    |
    ONCT-534